Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Breast Cancer (Tokyo, Japan)|June 13, 2023
Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectivesSumito Saeki, Tsuguo Iwatani, Atsuko Kitano, et al.
International Journal of Clinical Oncology|November 23, 2011
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancerYuko Tanabe, Kenji Hashimoto, Chikako Shimizu, et al.
Oncotarget|October 23, 2018
Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profilesTakeshi Sawada, Riet Hilhorst, Savithri Rangarajan, et al.
Biochemical and Biophysical Research Communications|September 3, 2010
Transmission of circulating cell-free AA amyloid oligomers in exosomes vectors via a prion-like mechanismMasayoshi Tasaki, Mitsuharu Ueda, Sho Ochiai, et al.
Data in Brief|September 19, 2022
Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancerYukinori Ozaki, Junji Tsurutani, Toru Mukohara, et al.
Urologic Oncology|March 13, 2017
Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinomaYuji Miura, Naoko Inoshita, Masaomi Ikeda, et al.
Cancer Science|March 19, 2016
Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patientsKenji Tamura, Hirofumi Mukai, Yoichi Naito, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2016
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancerYutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, et al.
Cancer Chemotherapy and Pharmacology|March 3, 2016
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumorsKenji Tamura, Jun Hashimoto, Yuko Tanabe, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, et al.
Pageof 11